Real World Experience in Heart Failure With Reduced Ejection Fraction (HFrEF) Patients Treated With sAc/vaL.
Status
Conditions
Treatments
Details and patient eligibility
About
The study is a cohort observational, retrospective, non-interventional study.
Full description
Study period:
Index date: The index date were defined as the first date of the first prescription of Sacubitril/Valsartan during inclusion period and this were used to establish the beginning of the follow-up period.
Characterization period: 6 months period before the index date were used to characterize patients.
Follow-up period: Any patients has at least 1 year of follow-up. Follow-up period went from index date to June 2020.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Consecutive ambulatory patients with a diagnosis of HF that attended the Outpatient Clinics for HF management and who have been prescribed Sacubitril/Valsartan from 01 October 2016 to 30 June 2019 (inclusion period) were included in the study. To allow for at least 1-year follow-up period for any patients, the observation period ended by 30 June 2020.
In detail, all patients attending by outpatient clinics for the diagnosis and treatment of HF in the Italian Centers involved, with:
- age ≥18 years old AND
- at least one prescription of Sacubitril/Valsartan from 01 October 2016 to 30 June 2019 were included in the study.
Exclusion criteria
- Missing age or sex information.
Trial design
924 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal